Role of p-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra

Pharmaceutical Research

Volumn 24, Issue 9, 2007, Pages 1668-1690

  Yu, Xi Yong ^a   Lin, Shu Guang ^a   Zhou, Zhi Wei ^b   Chen, Xiao ^c   Liang, Jun ^d   Yu, Xue Qing ^c   Chowbay, Balram ^e   Wen, Jing Yuan ^f   Duan, Wei ^g   Chan, Eli ^h   Li, Xiao Tian ⁱ   Cao, Jie ^j   Li, Chun Guang ^k   Xue, Charlie Changli ^k   Zhou, Shu Feng ^l  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b NANCHANG UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF SYDNEY   (Australia)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g DEAKIN UNIVERSITY   (Australia)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ FUDAN UNIVERSITY   (China)

^j GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^k RMIT UNIVERSITY   (Australia)

^l QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

more..

Author keywords

Brain blood barrier; Glabridin; In situ brain perfusion; mdr1a knockout mouse; P glycoprotein; Rat brain microvascular endothelial cell

Indexed keywords

GLABRIDIN; GLYCOPROTEIN P; GLYCYRRHIZA GLABRA EXTRACT; ISOFLAVAN DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; QUINIDINE; SUCROSE; VERAPAMIL; VERLUKAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; ENDOTHELIAL CELLS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PERMEABILITY; PHENOLS; QUINIDINE; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL;

EID: 34547631062     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9297-1     Document Type: Article

References (55)

1. W. A. Banks. Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J. Neurovirol. 5:538-555 (1999).
2. W. Loscher and H. Potschka. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98 (2005).
3. P. L. Golden and G. M. Pollack. Blood-brain barrier efflux transport. J. Pharm. Sci. 92:1739-1753 (2003).
4. P. Borstand and R. O. Elferink. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71:537-592 (2002).
5. H. Sun, H. Dai, N. Shaik, and W. F. Elmquist. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 55:83-105 (2003).
6. A. G. de Boer, I. C. van der Sandt, and P. J. Gaillard. The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol. 43:629-656 (2003).
7. T. Terasaki and S. Ohtsuki. Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology. NeuroRx 2:63-72 (2005).
8. D. J. Begley. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10:1295-1312 (2004).
9. M. Demeule, A. Regina, J. Jodoin, A. Laplante, C. Dagenais, F. Berthelet, A. Moghrabi, and R. Beliveau. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul. Pharmacol. 38:339-348 (2002).
10. E. M. Taylor. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin. Pharmacokinet. 41:81-92 (2002).
11. Y.-P. Zhu. Chinese materia medica: chemistry, pharmacology and applications, Harwood Academic Publishers, Amsterdam, The Netherlands, 1998.
12. R. K. Dhiman and Y. K. Chawla. Herbal medicines for liver diseases. Dig. Dis. Sci. 50:1807-1812 (2005).
13. C. Fiore, M. Eisenhut, E. Ragazzi, G. Zanchin, and D. Armanini. A history of the therapeutic use of liquorice in Europe. J. Ethnopharmacol. 99:317-324 (2005).
14. L. Bielory. Complementary and alternative interventions in asthma, allergy, and immunology. Ann. Allergy Asthma Immunol. 93:S45-S54 (2004).
15. W. J. Craig. Health-promoting properties of common herbs. Am. J. Clin. Nutr. 70:491S-499S (1999).
16. P. A. Belinky, M. Aviram, B. Fuhrman, M. Rosenblat, and J. Vaya. The antioxidative effects of the isoflavan glabridin on endogenous constituents of LDL during its oxidation. Atherosclerosis 137:49-61 (1998).
17. T. Yokota, H. Nishio, Y. Kubota, and M. Mizoguchi. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res. 11:355-361 (1998).
18. M. Rosenblat, P. Belinky, J. Vaya, R. Levy, T. Hayek, R. Coleman, S. Merchav, and M. Aviram. Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cell-mediated oxidation of low density lipoprotein. A possible role for protein kinase C. J. Biol. Chem. 274:13790-13799 (1999).
19. S. Tamir, M. Eizenberg, D. Somjen, N. Stern, R. Shelach, A. Kaye, and J. Vaya. Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells. Cancer Res. 60:5704-5709 (2000).
20. F. Aoki, S. Honda, H. Kishida, M. Kitano, N. Arai, H. Tanaka, S. Yokota, K. Nakagawa, T. Asakura, Y. Nakai, and T. Mae. Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet-induced obese C57BL/6J mice. Biosci. Biotechnol. Biochem. 71:206-214 (2007).
21. J. S. Kang, Y. D. Yoon, M. H. Han, S. B. Han, K. Lee, K. H. Lee, S. K. Park, and H. M. Kim. Glabridin suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking sphingosine kinase pathway: implications of Akt, extracellular signal-regulated kinase, and nuclear factor-kappaB/Rel signaling pathways. Mol. Pharmacol. 69:941-949 (2006).
22. R. K. Dhiman. Herbal hepatoprotective agents: marketing gimmick or potential therapies? Trop. Gastroenterol. 24:160-162 (2003).
23. Z. Y. Wang and D. W. Nixon. Licorice and cancer. Nutr. Cancer 39:1-11 (2001).
24. C. E. Piersen. Phytoestrogens in botanical dietary supplements: implications for cancer. Integr. Cancer Ther. 2:120-138 (2003).
25. D. Armanini, C. Fiore, M. J. Mattarello, J. Bielenberg, and M. Palermo. History of the endocrine effects of licorice. Exp. Clin. Endocrinol. Diabetes 110:257-261 (2002).
26. L. Langmead and D. S. Rampton. Review article: herbal treatment in gastrointestinal and liver disease-benefits and dangers. Aliment. Pharmacol. Ther. 15:1239-1252 (2001).
27. A. Olukoga and D. Donaldson. Liquorice and its health implications. J. R. Soc. Health 120:83-89 (2000).
28. J. Cao, X. Chen, J. Liang, X. Q. Yu, A. L. Xu, E. Chan, W. Duan, M. Huang, J. Y. Wen, X. Y. Yu, X. T. Li, F. S. Sheu, and S. F. Zhou. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. Drug. Metab. Dispos. 35:539-553 (2007).
29. F. Roux and P. O. Couraud. Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cell. Mol. Neurobiol. 25:41-58 (2005).
30. T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63 (1983).
31. S. Zhou, X. Feng, P. Kestell, J. W. Paxton, B. C. Baguley, and E. Chan. Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4- acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. Eur. J. Pharm. Sci. 24:513-524 (2005).
32. B. El Hafny, N. Cano, M. Piciotti, A. Regina, J. M. Scherrmann, and F. Roux. Role of P-glycoprotein in colchicine and vinblastine cellular kinetics in an immortalized rat brain microvessel endothelial cell line. Biochem. Pharmacol. 53:1735-1742 (1997).
33. Q. Tian, J. Zhang, E. Chan, W. Duan, and S. F. Zhou. Multidrug resistance proteins (MRPs) and implication in drug development. Drug Dev. Res. 51:1-18 (2005).
34. J. Zhang, M. Huang, S. Guan, H. C. Bi, Y. Pan, W. Duan, S. Y. Chan, X. Chen, Y. H. Hong, J. S. Bian, H. Y. Yang, and S. Zhou. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. J. Pharmacol. Exp. Ther. 317:1285-1294 (2006).
35. Y. Takasato, S. I. Rapoport, and Q. R. Smith. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247:H484-H493 (1984).
36. I. Tamai, M. Senmaru, T. Terasaki, and A. Tsuji. Na(+)- and Cl(-)-dependent transport of taurine at the blood-brain barrier. Biochem. Pharmacol. 50:1783-1793 (1995).
37. S. P. Khor and M. Mayersohn. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations. Drug Metab. Dispos. 19:478-485 (1991).
38. V. C. de Boer, A. A. Dihal, H. van der Woude, I. C. Arts, S. Wolffram, G. M. Alink, I. M. Rietjens, J. Keijer, and P. C. Hollman. Tissue distribution of quercetin in rats and pigs. J. Nutr. 135:1718-1725 (2005).
39. U. K. Laemmli. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685 (1970).
40. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
41. K. Yamaoka, T. Nakagawa, and T. Uno. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-167 (1978).
42. S. Zhou, L. Y. Lim, and B. Chowbay. Herbal modulation of P-glycoprotein. Drug Metab. Rev. 36:57-104 (2004).
43. T. Miyama, H. Takanaga, H. Matsuo, K. Yamano, K. Yamamoto, T. Iga, M. Naito, T. Tsuruo, H. Ishizuka, Y. Kawahara, and Y. Sawada. P-glycoprotein- mediated transport of itraconazole across the blood-brain barrier. Antimicrob. Agents Chemother. 42:1738-1744 (1998).
44. S. V. Ambudkar, C. O. Cardarelli, I. Pashinsky, and W. D. Stein. Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J. Biol. Chem. 272:21160-21166 (1997).
45. C. J. Ek, M. D. Habgood, K. M. Dziegielewska, A. Potter, and N. R. Saunders. Permeability and route of entry for lipid-insoluble molecules across brain barriers in developing Monodelphis domestica. J. Physiol. 536:841-853 (2001).
46. S. Ohtsuki, S. Sato, H. Yamaguchi, M. Kamoi, T. Asashima, and T. Terasaki. Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells. J. Cell. Physiol. 210:81-86 (2007).
47. A. H. Schinkel, J. J. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. van Deemter, C. A. Mol, M. A. van der Valk, E. C. Robanus-Maandag, H. P. te Riele, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502 (1994).
48. J. van Asperen, O. van Tellingen, F. Tijssen, A. H. Schinkel, and J. H. Beijnen. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer 79:108-113 (1999).
49. N. Drion, M. Lemaire, J. M. Lefauconnier, and J. M. Scherrmann. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J. Neurochem. 67:1688-1693 (1996).
50. M. Lemaire, A. Bruelisauer, P. Guntz, and H. Sato. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother. Pharmacol. 38:481-486 (1996).
51. M. Arboix, O. G. Paz, T. Colombo, and M. D'Incalci. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J. Pharmacol. Exp. Ther. 281:1226-1230 (1997).
52. S. Song, H. Suzuki, R. Kawai, and Y. Sugiyama. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab. Dispos. 27:689-694 (1999).
53. A. H. Schinkel, U. Mayer, E. Wagenaar, C. A. Mol, L. van Deemter, J. J. Smit, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, J. M. Zijlmans, W. E. Fibbe, and P. Borst. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 94:4028-4033 (1997).
54. S. Baltes, A. M. Gastens, M. Fedrowitz, H. Potschka, V. Kaever, and W. Loscher. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52:333-346 (2007).
55. M. Katoh, N. Suzuyama, T. Takeuchi, S. Yoshitomi, S. Asahi, and T. Yokoi. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J. Pharm. Sci. 95:2673-2683 (2006).